Back to Ovarian Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02151370

NCT02151370
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You must be a woman aged 18 or older
  • You must have been diagnosed with advanced epithelial ovarian cancer, confirmed through a tissue sample (biopsy)
  • You must have had a build-up of fluid in the abdomen (ascites) before surgery
  • You must have some cancer remaining after surgery (residual disease)
  • You must either have never received chemotherapy before, or have had only one previous round of chemotherapy treatment for this cancer
  • Your cancer must be at a specific advanced stage, known as FIGO stage IIIb or stage IV
  • You must be well enough to carry out basic daily activities — your doctor will assess this using a standard scale (confirm with trial site)
  • Your doctor must confirm that you are suitable to receive the drug Avastin (bevacizumab) combined with chemotherapy, based on medical guidelines

Who may not be able to join:

  • You are pregnant or currently breastfeeding
  • Your tumour is classified as low grade (slow-growing), or your cancer was completely removed during surgery
  • You have high blood pressure that cannot be controlled with medication
  • You have unexplained bleeding
  • You have had an allergic reaction to bevacizumab (Avastin) or any of its ingredients
  • You have any other medical conditions or factors that would make it unsafe for you to receive Avastin or the chemotherapy used in this trial, as determined by your doctor (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Hoffmann-La Roche
Registry
clinicaltrials_gov
Start date
1 March 2013
Est. completion
1 September 2013

Where this trial is recruiting

El Salvador

Primary endpoints

The proportion of patients who require paracenthesis during treatment with Avastin; The amount of ascitic fluid extracted during treatment with Avastin

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov